Background GenzymeLimited ("Genzyme”) is the manufacturer of Ceredase and Cerezyme, drugs used in the treatment of Gaucher disease. Genzyme also provided home care services to administer its drugs. The home care services were initially subcontracted, firstly to Caremark and then to Healthcare at Home (“HH”). From April 2001, Genzyme provided home care services through its own integrated service - GenzymeHomecare. In May 2001, Genzyme terminated its contract with HH. From May 2001, HH (and other independent delivery/homecare service providers) were only able to obtain Cerezyme from Genzyme at the National Health Service (“NHS”) list price, which included the cost of the provision of homecare services. HH complained to the Office of Fair Trading (the "OFT") about Genzyme's pricing
Share on
|
|
The UK Competition Appeal Tribunal grants interim damages in a case of abusive drugs price setting (Healthcare at Home / Genzyme)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
